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SHORT REPORT
Aberrant gene methylation implicated in the progression of
monoclonal gammopathy of undetermined significance to
multiple myeloma
Chor-Sang Chim, Raymond Liang, Man-Hin Leung, Yok-Lam Kwong
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J Clin Pathol 2007;60:104–106. doi: 10.1136/jcp.2006.036715
Malignant transformation is a multistep process that may
involve dysregulation of oncogenes and tumour suppressor
genes, and monoclonal gammopathy of undetermined sig-
nificance (MGUS) is believed to be a precursor of multiple
myeloma. To investigate whether aberrant promoter methyla-
tion might be involved in the evolution of MGUS to multiple
myeloma, we examined the p16, protein tyrosine phosphatase,
non-receptor type 6 (SHP1), death-associated protein (DAP)
kinase, E-cadherin and oestrogen receptor genes, most being
tumour suppressor genes, by methylation-specific polymerase
chain reaction. In 32 cases of multiple myeloma and 19 cases
of MGUS, significantly more frequent methylation of p16
(p = 0.001), SHP1 (p(0.001) and E-cadherin (p(0.001)
genes was found in multiple myeloma than in MGUS.
Methylation of DAP kinase and oestrogen receptor genes was
comparable in multiple myeloma and MGUS. In conclusion,
methylation of p16, SHP1 and E-cadherin genes might be
involved in the progression of MGUS to multiple myeloma.
O
ncogenesis is a multistep process involving dysregula-
tion of oncogenes and tumour suppressor genes.
Multiple myeloma is characterised by neoplastic pro-
liferation of monoclonal plasma cells. Multiple myeloma cells
arise from postgerminal centre B cells, which migrate to the
bone marrow, adhere to the stroma, proliferate, and trigger
subsequent bone resorption and a paracrine cytokine loop.1 2
The disease may progress from monoclonal gammopathy of
undetermined significance (MGUS) to multiple myeloma.
MGUS occurs in approximately 3% of people .70 years old.2
Multiple myeloma develops in about one quarter of MGUS
patients after a median of 10 years.3 Therefore, MGUS is
regarded as a precursor of multiple myeloma, with the rate of
transformation to multiple myeloma estimated to be 1% per
year.3
DNA methylation involves the addition of a methyl group to
the carbon 5 position of the cytosine ring in CpG dinucleotide.
At gene promoters, DNA methylation leads to recruitment of a
transcriptional repressor complex, resulting in suppression of
transcription.4 In cancers, the CpG islands of selected genes are
aberrantly methylated, resulting in silencing of these genes.
Therefore, methylation is an alternative mechanism of gene
inactivation, in addition to deletion and mutation.
Frequent methylation of the oestrogen receptor, E-cadherin,
protein tyrosine phosphatase, non-receptor type 6 (SHP1), death-
associated protein (DAP) kinase and p16 genes has been shown in
multiple myeloma.5–7 During the evolution of MGUS to multiple
myeloma, multiple genetic aberrations are sequentially
acquired. In this study, we tested the hypothesis that aberrant
promoter methylation might be one of the steps involved in the
progression of MGUS to multiple myeloma.
MATERIALS AND METHODS
Patients, diagnosis and treatment
Diagnosis of MGUS was based on an asymptomatic monoclonal
gammopathy (immunoglobulin G (IgG)(3.5 g/dl, IgA(2 g/dl,
and urinary Bence Jones protein(1 g/24 h), ,10% plasma cells
in the bone marrow and absence of lytic bone lesions. Diagnosis
of multiple myeloma was based on standard criteria.3
Monoclonal paraproteins were identified by serum electrophor-
esis, immunoelectrophoresis or immunofixation. The study was
approved by the review board of Queen Mary Hospital, Hong
Kong.
Methylation-specific polymerase chain reaction
High-molecular-weight DNA was isolated by standard protocols
from bone marrow aspirates at diagnosis, and from eight
marrow aspirates of healthy donors. Methylation-specific
polymerase chain reaction (MSP) was performed as described.6
Briefly, treatment of DNA with bisulphite for conversion of
unmethylated, but not methylated, cytosine to uracil was
performed with the CpGenome DNA modification kit (Intergen,
New York, New York, USA). Primers for the methylated MSP
and unmethylated MSP gene promoter regions were as
described previously (fig 1). In all experiments, DNA from
normal donors was used as negative control, and methylated
control DNA (CpGenome Universal Methylated DNA, Intergen)
as positive control. MSP was performed in a thermal cycler
(9700, Perkin-Elmer Biosystems, Foster City, California, USA).
The polymerase chain reaction mixture contained 50 ng of
bisulphite-treated DNA, 0.2 mM deoxynucleoside tripho-
sphates, 2 mM MgCl2, 10 pmol of each primer, 16PCR buffer
II and 2.5 U AmpliTaq Gold (Perkin-Elmer Biosystems) in a
final volume of 25 ml. The identity of the MSP products was
confirmed by DNA sequencing.
Statistical analysis
Frequencies of gene methylation in multiple myeloma and
MGUS were compared by x2 or Fisher’s exact test (SPSS V.12).
p Values are two sided.
RESULTS
Methylation-specific polymerase chain reaction
The positive control, but none of the eight normal marrow DNA
samples, showed complete methylation of DAP kinase, p16,
SHP1, E-cadherin and oestrogen receptor genes (fig 1). In samples
showing negative methylated-MSP amplification, integrity of
DNA was confirmed by positive unmethylated-MSP amplifica-
tion.
Abbreviations: DAP, death-associated protein; MGUS, monoclonal
gammopathy of undetermined significance; MSP, methylation-specific
polymerase chain reaction; SHP1, protein tyrosine phosphatase, non-
receptor type 6.
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MSP of multiple myeloma and MGUS
There were 32 patients with multiple myeloma and 19 patients
with MGUS (table 1). Frequencies of methylation of DAP kinase
and oestrogen receptor genes were comparable in multiple
myeloma and MGUS. E-cadherin gene methylation was found
only in multiple myeloma (p,0.001). p16 and SHP1 methyla-
tion was significantly more frequent in multiple myeloma than
in MGUS (p16 53.1% v 5.3%, p,0.001; SHP1 84.4% v 31.6%,
p,0.001; fig 1, table 2).
DISCUSSION
Our study is based on the hypothesis that if methylation of
these genes were involved in the progression of MGUS to
multiple myeloma, the frequency of gene hypermethylation
would be significantly higher than that of MGUS. On the other
hand, if hypermethylation of these genes were part of the
initiating event that leads to immortalisation of the plasma cell,
the frequency of hypermethylation of these genes in multiple
myeloma would be expected to be comparable to that of MGUS.
We showed that p16, SHP1 and E-cadherin gene methylation was
significantly more frequent in multiple myeloma than in
MGUS, suggesting that methylation of these genes might be
involved in clonal evolution of MGUS to multiple myeloma.
p16 is a cyclin-dependent kinase inhibitor targeting cyclin-
dependent kinases 4 and 6. We showed preferential methyla-
tion of p16 in multiple myeloma. Previous studies have also
shown more frequent p16 methylation in multiple myeloma
than in MGUS.8 9 Furthermore, p16 methylation was also more
frequent in plasma-cell leukaemia.10 However, in CD138-
purified plasma cells, p16 methylation has been found to be
equally frequent in MGUS and multiple myeloma.10
E-cadherin, a homotypic cell adhesion molecule, is consid-
ered a suppressor of metastasis. Our finding of preferential E-
cadherin gene methylation in multiple myeloma instead of
MGUS was consistent with previous reported results.10 As the
progression of MGUS involves metastasis of the myeloma
plasma cells to other parts of the bone marrow, E-cadherin gene
methylation might be expected to play a role in the evolution of
MGUS to multiple myeloma.
SHP1, a cytoplasmic protein tyrosine phosphatase, is a
putative tumour suppressor negatively regulating the inter-
leukin 6/Jak/STAT signalling in plasma cells.6 In myeloma cells
with complete SHP1 methylation, STAT3 was constitutively
activated. Demethylation with re-expression of SHP1 led to
down regulation of phosphorylated STAT3, showing that SHP1
methylation is biologically relevant in myeloma pathogenesis.6
Taken together, p16 and SHP1 gene methylation might confer
a proliferative and survival advantage on neoplastic plasma
cells, and E-cadherin gene methylation might enhance the
metastatic potential and thus progression of MGUS.
Similar to another study,11 we showed a comparable
frequency of DAP kinase methylation in patients with MGUS
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Figure 1 Methylation-specific polymerase chain reaction of death-associated protein kinase (DAPK) , p16, suppressor of high-copy PP1 (SHP1), E-
cadherin (ECAD) and oestrogen receptor (ER) genes in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).
Samples tested were marrow aspirates obtained at diagnosis. The sequences for primers were DAPK (methylated, forward: 59-GGA TAG TCG GAT CGA
GTT AAC GTC-39, reverse: 59-CCC TCC CAA ACG CCG A-39; unmethylated, forward: 59-GGA GGA TAG TTG GAT TGA GTT AAT GTT-39, reverse: 59-
CAA ATC CCT CCC AAA CAC CAA-39), p16 (methylated, forward: 59-TTA TTA GAG GGT GGG GCG GAT CGC-39, reverse: 59-GAC CCC GAA CCG
CGA CCG TAA-39; unmethylated, forward: 59-TTA TTA GAG GGT GGG GTG GAT TGT-39, reverse: 59-TTA TTA GAG GGT GGG GTG GAT TGT-39),
SHP1 (methylated, forward: 59-GAA CGT TAT TAT AGT ATA GCG TTC-39, reverse: 59-TCA CGC ATA CGA ACC CAA ACG-39; unmethylated, forward: 59-
GTG AAT GTT ATT ATA GTA TAG TGT TTG G-39, reverse: 59-TTC ACA CAT ACA AAC CCA AAC AAT-39), E-cadherin (methylated, forward: 59-GTG
GGC GGG TCG TTA GTT TC-39, reverse: 59-CTC ACA AAT ACT TTA CAA TTC CGA CG-39; unmethylated, forward: 59-GGT GGG TGG GTT GTT AGT TTT
GT-39, reverse: 59-AAC TCA CAA ATC TTT ACA ATT CCA ACA-39) and oestrogen receptor (methylated, forward: 59-CGA GTT GGA GTT TTT GAA TCG
TTC-39, reverse: 59-CTA CGC GTT AAC GAC GAC CG-39; unmethylated: forward: 59-ATG AGT TGG AGT TTT TGA ATT GTT T-39, reverse: 59-ATA AAC
CTA CAC ATT AAC AAC AAC CA-39). MW, molecular weight markers; U, unmethylated MSP; M, methylated MSP; B, reagent blank; N, normal negative
control; P, methylated positive control; S1–S4, four MGUS marrow samples; M1–M4, four primary myeloma marrow samples.
Aberrant gene methylation 105
www.jclinpath.com
 on 13 October 2008 jcp.bmj.comDownloaded from 
and multiple myeloma, implying that DAP kinase is probably not
involved in the progression of MGUS. However, there was a
relatively high frequency of DAP kinase methylation (35.7%) in
MGUS, suggesting that this might be involved in the develop-
ment of MGUS.
Ideally, methylation of p16, E-cadherin and SHP1 genes should
be investigated serially in MGUS and multiple myeloma
samples in the same patient. However, as the annual rate of
progression of MGUS to multiple myeloma is only 1%, this
would require a long period of observation.
In conclusion, there was preferential methylation of some
tumour suppressor genes in MGUS. Therefore, inactivation of
tumour suppressor genes by gene methylation might contribute
to disease progression from MGUS to multiple myeloma.
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Table 1 Demographic data of patients with monoclonal
gammopathy of undetermined significance and multiple
myeloma
MGUS MM
n 19 32
Sex
Male 10 (52.6%) 17 (53.1%)
Female 9 (47.4%) 15 (46.9%)
Age (years)
Median 76 63
Range 55–85 25–87
Paraprotein subtype
IgG 12 (85.7%) 18 (56.3%)
IgA 2 (14.3%) 8 (25.0%)
IgD 1 (3.1%)
Light chain 5 (15.6%)
Bone marrow
plasma cells
3–7% 38–93%
Paraprotein level
Median – 37.5 g/l
Range – 12–78 g/l
Durie–Salmon stage
I – 4 (12.5%)
II – 9 (28.1%)
III – 19 (59.4%)
–, not applicable.
MGUS, monoclonal gammopathy of undetermined significance; MM,
multiple myeloma.
Table 2 Frequencies of aberrant methylation of death-
associated protein kinase, p16, SHP1, E-cadherin and
oestrogen receptor genes
MGUS MM (%) p Value
n 19 32
DAP kinase
M 6 (31.6) 18 (56.3) 0.146
U 13 (68.4) 14 (43.7)
p16
M 1 (5.3) 17 (53.1) 0.001
U 18 (94.7) 15 (46.9)
SHP1
M 6 (31.6) 27 (84.4) ,0.001
U 13 (68.4) 5 (15.6)
ECAD
M 0 (0) 18 (56.3) ,0.001
U 19 (100) 14 (43.7)
ER
M 3 (15.8) 13 (40.6) 0.117
U 16 (84.2) 19 (59.3)
DAP, death-associated protein gene; ECAD, E-cadherin gene; ER, oestrogen
receptor gene; M, methylated gene status; MGUS, monoclonal gammopathy
of undetermined significance; MM, multiple myeloma; SHP1, suppressor of
high-copy PP1 gene; U, unmethylated gene status.
M and U values are n (%).
Take-home messages
N Tumour suppressor genes are implicated in the patho-
genesis of multiple myeloma.
N Hypermethylation of ECAD, SHP1 and p16 is implicated
in the progression from MGUS to mutiple myeloma.
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